The national incidence and clinical picture of SLE in children in Australia - A report from the Australian Paediatric Surveillance Unit

Lupus

Volumn 24, Issue 1, 2015, Pages 66-73

  MacKie, F E ^a   Kainer, G ^a   Adib, N ^b   Boros, C ^c   Elliott, E J ^d   Fahy, R ^e   Munro, J ^f   Murray, K ^g   Rosenberg, A ^a   Wainstein, B ^h   Ziegler, J B ^h   Singh Grewal, D ^h  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Queensland Paediatric Rheumatology Services ^*  (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ALICE SPRINGS HOSPITAL   (Australia)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

^g PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^h SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

Australian Aboriginal and Torres Strait Islanders; incidence; lupus nephritis; Systemic lupus erythematosus

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; LUPUS ANTICOAGULANT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; PREDNISONE; RITUXIMAB; ANTINUCLEAR ANTIBODY;

ADOLESCENT; ARTICLE; AUSTRALIAN ABORIGINE; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; DISEASE SURVEILLANCE; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; KIDNEY BIOPSY; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PROSPECTIVE STUDY; QUESTIONNAIRE; RARE DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TORRES STRAIT ISLANDER; ASIAN CONTINENTAL ANCESTRY GROUP; AUSTRALIA; BLOOD; DISEASE COURSE; ETHNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; OCEANIC ANCESTRY GROUP; ONSET AGE; PATHOLOGY; PRESCHOOL CHILD; PROTEINURIA; RHEUMATIC FEVER; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; AGE OF ONSET; ANTIBODIES, ANTINUCLEAR; ASIAN CONTINENTAL ANCESTRY GROUP; AUSTRALIA; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; OCEANIC ANCESTRY GROUP; PROSPECTIVE STUDIES; PROTEINURIA; RHEUMATIC FEVER;

EID: 84918562584     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314552118     Document Type: Article

References (52)

1. Ballou SP, Khan MA, Kushner I. Clinical features of systemic lupus erythematosus. Differences related to race and age of onset. Arthritis Rheum. 1982 ; 25: 55-60
2. Tucker LB, Menan S, Schaller JG, Isenberg DA. Adult and childhood onset systemic lupus erythematosus: A comparison of onset, clinical features, serology and outcome. Br J Rheumatol. 1995 ; 34: 866-872
3. Kamphuis S, Silverman ED. Prevalence and burden of pediatric onset systemic lupus erythematosus. Nat Rev Rheum. 2010 ; 6: 538-546
4. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus. 2006 ; 15: 308-318
5. Dolezalová P, Telekesová P, Nemcová D, Hoza J. Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey. J Rheum. 2004 ; 31: 2295-2299
6. Jonsson H, Nived O, Sturfelt G, Silman A. Estimating the incidence of SLE in a defined population using multiple sources of retrieval. Br J Rheumatol. 1990 ; 29: 185-188
7. Fujikawa S, Okuni M. A nationwide surveillance study of rheumatic diseases among Japanese children. Acta Paediatr Jpn. 1997 ; 39: 242-244
8. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease and rare vasculitides in children of different ethnic origins. Lancet. 2002 ; 360: 1197-1202
9. Kaipiainen-Seppänen O, Savolainen A. Incidence of chronic juvenile rheumatic diseases in Finland during 1980-1990. Clin Exp Rheumatol. 1996 ; 14: 441-444
10. Uramoto KM, Michet CJ, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. 1999 ; 42: 46-50
11. Zandman-Goddard G, Solomon M, Rosman Z, Peeva E, Shoenfeld Y. Environment and lupus-related diseases. Lupus. 2012 ; 21: 241-250
12. Wysenbeek AJ, Block DA, Fries JF. Prevalence and expression of photosensitivity in systemic lupus erythematosus. Ann Rheum Dis. 1989 ; 48: 461-463
13. Wang GS, Zhang M, Li XP, et al. Ultraviolet B exposure of peripheral blood mononuclear cells of patients with systemic lupus erythematosus inhibits DNA methylation. Lupus. 2009 ; 18: 1037-1044
14. Segasothy M, Phillips PA. Systemic lupus erythematosus in Aborigines and Caucasians in central Australia: A comparative study. Lupus. 2001 ; 10: 439-444
15. Lehmann P, Holze E, Kind P, Goerz G, Plewig G. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Derm. 1990 ; 22: 181-187
16. Tan EM, Cohen AS, Fries JF, et al. The 1982 Revised Criteria for the Classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
17. U.S. Department of Health and Human Services. The Fourth Report on Diagnosis, Evaluation and Treatment of High Blood Pressure in Children and Adolescents, http://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp-ped.pdf (accessed 5 May 2005).
18. Australian Bureau of Statistics, http://www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/BD1B52D132D130E7CA2573630012F67B?opendocument (accessed 15 October 2013).
19. Australian Bureau of Statistics, 3235 Population by age and sex, regions of Australia 2010 www.abs.gov.au/Ausstats/abs@nsf/mf/3235.0 (accessed 15 October 2013).
20. Petri M, Orbai A, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 ; 64: 2677-2686
21. Pelkonen PM, Jalanko HJ, Lanto RR, et al. Incidence of systemic connective tissue diseases in children: A nationwide prospective study in Finland. J Rheum. 1994 ; 21: 2143-2143
22. Huemer C, Huemer M, Dorner T, et al. Incidence of pediatric rheumatic diseases in a regional population in Austria. J Rheum. 2001 ; 28: 2116-2119
23. Pineles D, Valente A, Warren B, Petersen MG, Lehman TJ, Moorthy LN. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus. 2011 ; 20: 1187-1192
24. McCarty DJ, Manzi S, Medsger TA, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus race and gender differences. Arthritis Rheum. 1995 ; 38: 1260-1270
25. Peschken CA, Katz S, Silverman E, et al. The 1000 Canadian faces of lupus: Determinants of disease outcome in a large multiethnic cohort. J Rheumatol. 2009 ; 36: 1200-1208
26. Hiraki LT, Benseler SM, Tyrrell PN, Harvey E, Hebert D, Silverman ED. Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol. 2009 ; 36: 2539-2546
27. Fremantle E, Zurynski YA, Mahajan D, D'Antoine H, Elliott EJ. Indigenous child health: Urgent need for improved data to underpin better health outcomes. Med J Aust. 2008 ; 188: 588-591
28. Grennan DM, Bossingham D. Systemic lupus erythematosus (SLE): Different prevalences in different populations of Australian Aboriginals. Aust N Z J Med. 1995 ; 25: 182-183
29. Anstey N, Dunckley H, Bastian I, Currie B. Systemic lupus erythematosus in Australian Aborigines: High prevalence, morbidity and mortality. Aust N Z J Med. 1993 ; 23: 645-651
30. Bloor G, Rigby RJ, Richmond JM, Zilko PJ, Dawkins RL. Systemic lupus erythematosus in Australian Aborigines. Aust N Z J Med. 1982 ; 12: 553-553
31. Ranford P, Serjeantson SW, Hay J, Dunckley H. A high frequency of inherited deficiency of complement component C4 in Darwin Aborigines. Aust N Z J Med. 1987 ; 17: 420-423
32. Christiansen FT, Zhang WJ, Griffiths M, Mallal SA, Dawkins RL. Major histocompatibility complex (MHC) complement deficiency, ancestral haplotypes and systemic lupus erythematosis (SLE): C4 deficiency explains some but not all of the influence of the MHC. J Rheumatol. 1991 ; 18: 1350-1358
33. Council of Australian Governments. COAG Reform Council Health Care Report, 2010-2011, www.coagreformcouncil.gov.au (accessed 25 March 2013).
34. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: A longitudinal study. J Pediatr. 2008 ; 152: 550-556
35. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012 ; 71: 1771-1782
36. Dong J, Li H, Wang JB, Yao Y, Yang QR. Predictors for neuropsychiatric development in Chinese adolescents with systemic lupus erythematosus. Rheumatol Int. 2012 ; 32: 2681-2686
37. Hobbs DJ, Barletta G, Rajpal JS, et al. Severe paediatric systemic lupus erythematosus nephritis - a single-centre experience. Nephrol Dial Transplant. 2010 ; 25: 457-463
38. Baqi N, Moazami S, Singh A, Ahmad H, Balachandra S, Tejani A. Lupus nephritis in children: A longitudinal study of prognostic factors and therapy. J Am Soc Nephrol. 1996 ; 7: 924-929
39. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000 ; 35: 904-914
40. Moroni G, Ventura D, Riva P, et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis. 2004 ; 43: 28-36
41. Stewart JH, McCredie MR, McDonald SP. The incidence of treated end-stage renal disease in New Zealand Maori and Pacific Island people and in Indigenous Australians. Nephrol Dial Transplant. 2004 ; 19: 678-685
42. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 ; 20: 1103-1112
43. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005 ; 16: 1076-1084
44. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 ; 353: 2219-2228
45. Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: A systematic review and metaanalysis. J Rheumatol. 2011 ; 38: 69-78
46. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 ; 365: 1886-1895
47. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991 ; 324: 150-154
48. Fessler BJ, Alarcón GS, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005 ; 52: 1473-1480
49. Pons-Estel GJ, Alarcón GS, McGwin G, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009 ; 61: 830-839
50. Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010 ; 62: 863-868
51. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology Guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 ; 64: 797-808
52. Zurynski Y, Elliott EJ. Australian Paediatric Surveillance Unit annual report, 2010. Comm Dis Intell Q Rep. 2011 ; 35: 244-249